Alembic Pharma Q3 net up 281% at Rs 269 cr

Net sales for quarter under review stood at Rs 931 c

Vadodara-based Alembic Pharmaceuticals Ltd posted a 281% rise in its consolidated net profit after tax for the quarter ended December 31, 2015 to Rs 269 crore primarily on the back of a 248% jump in revenues from its international business.

The net sales for the quarter under review stood at Rs 931 crore, up 81% on a year-on-year basis. The company's India branded business was up by around 15% to Rs 288 crore, while its international business did well to clock a 248% growth touching Rs 521 crore. The active pharmaceutical ingredients (API) business also grew by 24% during the quarter to touch Rs 101 crore.

Shaunak Amin, joint managing director, Alembic Pharmaceuticals said, "We have seen exceptional growth in all our businesses. The US business continues to outperform on the back of the Aripiprazole Generic launch. Our facilities have been in compliance and we have received 11 ANDA approvals this year."